Advertisement

Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81
Document › Details

Merck KGaA. (7/13/20). "Press Release: Changes in Merck Executive Board. Belén Garijo appointed Vice Chairman of the Executive Board and Deputy CEO – Udit Batra Leaves". Darmstadt.

Organisations Organisation Merck KGaA
  Group Merck (DE) (Group)
  Organisation 2 Waters Corporation (NYSE: WAT)
  Group Waters (Group)
Products Product reagents (bio/biochemical)
  Product 2 pharmaceutical
Persons Person Baillou, Johannes (Merck (DE) 201401– Chairman of Board of Partners E Merck KG)
  Person 2 Kuhnert, Marcus (Merck (DE) 201408– CFO before CFO of Henkel Laundry + Home Care businss unit)
     


> Belén Garijo appointed Vice Chairman of the Executive Board and Deputy CEO

> Udit Batra leaves the company to pursue other opportunities outside Merck

> Christos Ross will lead Life Science business sector on interim basis

> Marcus Kuhnert takes over additional Executive Board responsibility for Information Technology


The Board of Partners of E. Merck KG appointed Belén Garijo as Vice Chairman of the Executive Board and Deputy CEO of Merck KGaA effective today. She will maintain her current Executive Board responsibilities.

“The appointment of Belén Garijo as Vice Chairman of the Executive Board and Deputy CEO recognizes her outstanding achievements for our Healthcare business and her strong leadership in the critical corporate functions Human Resources and Environment, Health, Safety, Security, Quality”, said Johannes Baillou, Chairman of the Board of Partners of E. Merck KG.

Udit Batra has decided to pursue other opportunities outside Merck. Effective today, the contract of Mr. Batra as General Partner of E. Merck KG and Executive Board Member of Merck KGaA has been resolved.

“We would like to thank Udit Batra for nine years of service to our company, his great accomplishments and strong commitment towards science and technology. Together with his team, he ensured a successful integration of Sigma-Aldrich and continuously developed our global life science business. We wish him every success and all the very best for the future”, said Johannes Baillou.

The Board of Partners of E. Merck KG will decide about a successor in due course. On an interim basis, Christos Ross will take over the Life Science business lead, reporting to Stefan Oschmann, Chairman of the Executive Board and CEO. Ross joined Merck in 2008 and currently serves as Executive Vice President Integrated Supply Chain Operations within the Life Science business sector.

Belén Garijo joined Merck in 2011 as Chief Operating Officer of the Biopharma business and was appointed to the Executive Board in 2015. She is CEO of the Healthcare business and in charge of the corporate functions Human Resources and Environment, Health, Safety, Security, Quality.

Udit Batra joined Merck in 2011, took over responsibility for the Life Science business sector in 2014 and was appointed to the Executive Board in 2016. In 2017, he also assumed responsibility for Information Technology.

Marcus Kuhnert, Member of the Executive Board, Chief Financial Officer and in charge of Merck Business Services and Procurement, will in addition take over the Executive Board responsibility for Information Technology.


For more information, please contact Thomas Moeller
+49 151 1454-2005
Email


All Merck news releases are distributed by email at the same time they become available on the Merck website. Please go to www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.


About Merck

Merck, a leading science and technology company, operates across healthcare, life science and performance materials. Around 57,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2019, Merck generated sales of €16.2 billion in 66 countries.

Scientific exploration and responsible entrepreneurship have been key to Merck’s technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as EMD Serono in healthcare, MilliporeSigma in life science and EMD Performance Materials.

   
Record changed: 2020-07-29

Advertisement

Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81

More documents for Merck (DE) (Group)


To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to info@iito.de and simply fill the subject line with the word »MSC Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at Life-Sciences-Germany.com and Life-Sciences-Europe.com

Advertisement

Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81




» top